• Spyre Therapeutics, Inc. recently reported it has completed recruitment for the rheumatoid arthritis (RA) sub-study of its SKYWAY Phase 2 trial of SPY072, accelerating the expected topline readout to the third quarter of 2026, with additional proof-of-concept data for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) anticipated in the fourth quarter.
• The company is positioning SPY072, an extended half-life TL1A-targeting antibody, as a potentially more convenient rheumatic disease treatment with quarterly or twice-yearly subcutaneous maintenance dosing, a dosing profile that could be particularly important for patients needing long-term therapy.
• With this accelerated RA readout timeline for SPY072, we’ll explore how the strengthened clinical visibility may shape Spyre Therapeutics’ investment narrative.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Spyre Therapeutics' Investment Narrative?

To own Spyre Therapeutics, you have to buy into a pure clinical-stage story where value rests squarely on SPY072 and the broader TL1A and immunology platform. The completion of RA recruitment in the SKYWAY Phase 2 trial pulls the key SPY072 data catalyst into the third quarter of 2026, tightening the link between near-term share price moves and that readout, with additional PsA and axSpA proof-of-concept data following soon after. That clearer timeline may help justify some of the very large 1-year share price gains, but it also concentrates risk: the company still has no revenue, is running sizeable annual losses, and recently diluted shareholders through follow-on offerings to fund the pipeline. The new Chief Commercial Officer hire adds longer-term execution questions around how a small, unprofitable biotech might eventually bring any successful product to market.

However, investors should not overlook how much now rides on a single Phase 2 program outcome. Upon reviewing our latest valuation report, Spyre Therapeutics' share price might be too optimistic.

Exploring Other Perspectives

With only two fair value estimates from the Simply Wall St Community spanning roughly US$6 to over US$60, you are seeing how far apart private investors can be on Spyre. That spread sits against a story where accelerated SPY072 trial timelines raise the stakes on clinical execution and future financing, which could matter more for the company’s trajectory than any single valuation point right now.

Explore 2 other fair value estimates on Spyre Therapeutics - why the stock might be worth less than half the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Spyre Therapeutics research is our analysis highlighting 4 important warning signs that could impact your investment decision.
• Our free Spyre Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Spyre Therapeutics' overall financial health at a glance.

No Opportunity In Spyre Therapeutics?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Find 62 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.